CDK7の阻害は,MYCN誘発がんにおけるスーパーエンハンサー関連腫瘍転写を抑制する
Edmond Chipumuro1, Eugenio Marco2, Camilla L Christensen3
1Department of Pediatric Hematology/Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA 02215, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
Cell
|November 24, 2014
まとめ
サイクリン依存キナーゼ7 (CDK7) を標的にすることで,神経芽細胞腫におけるMYCN駆動遺伝子増幅を抑制する. このアプローチはマウスの腫瘍の成長を抑制し,全身の毒性なしで潜在的な新しいがん治療法を提供しました.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- がん遺伝学 がん遺伝学
背景:
- MYCオンコタンパク質は,遺伝子転写増幅によって腫瘍の成長を誘導する.
- MYCの機能を阻害することは,がん治療の課題となっています.
- 神経芽細胞腫はしばしばMYCNの増幅を伴い,攻撃的な疾患につながります.
研究 の 目的:
- MYCN増幅ニューロブラストーマにおけるサイクリン依存キナーゼ7 (CDK7) を阻害する治療の可能性を調査する.
- MYCN主導の転写と腫瘍の成長に対するCDK7抑制の影響を評価する.
主な方法:
- ニューロブラストーマ細胞におけるCDK7を標的とした共性阻害剤を使用した.
- MYCNオンコタンパク質のダウンレギュレーションとグローバル転写増幅を分析した.
- 高リスクの神経芽細胞腫のマウスモデルで評価された腫瘍の回帰と全身の毒性.
主要な成果:
- CDK7の阻害はMYCNのダウンレギュレーションにつながり,MYCN主導の転写増幅を抑制しました.
- 系統的毒性のないマウスモデルでは,腫瘍の有意な回帰が観察されました.
- 治療は,スーパー強化剤に関連する遺伝子をダウンレギュレーションすることによって,選択的にMYCN過剰発現する細胞を標的とした.
結論:
- CDK7抑制は,選択的にMYCN駆動の世界的転写増幅を標的とする.
- このアプローチは,神経芽細胞腫を含むMYC駆動がんに対する新しい治療戦略として有望であることが示されています.
- 転写メカニズムの選択的ターゲティングは,がん治療の新たな道を開く.
さらに関連する動画
関連する概念動画
02:34Inhibition of Cdk Activity
6.3K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
02:34Inhibition of CDK Activity
5.7K
5.7K
01:06Induced Pluripotent Stem Cells
6.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
6.4K
02:23Abnormal Proliferation
5.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
02:15M-Cdk Drives Transition Into Mitosis
6.8K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
02:38Mitogens and the Cell Cycle
8.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K